| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -8.0 | -9.4 |
| EPS (diluted, $ a share) | $-0.17 | $-0.31 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ANTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
AN2 Therapeutics, Inc.: key numbers
- Share price
- $4.47Close, Nov 16
- Market cap
- $170M
- Shares outstanding
- 37.94MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from AN2 Therapeutics, Inc.
All →AN2 Therapeutics Financial Results
AN2 Therapeutics reported financial results for the third quarter of 2026, highlighting a net loss of $11.4 million and a cash position of $51.4 million. The company is advancing its clinical pipeline, including the expected year-end enrollment initiation for its Phase 2 study of epetraborole in polycythemia vera and the selection of a new development candidate for hypophosphatasia.
- Term
- Q3 2026
“The third quarter was marked by continued execution across our clinical pipeline and meaningful progress in expanding the opportunities enabled by our boron chemistry platform. With FDA IND clearance for epetraborole in polycythemia vera, we now have the necessary regulatory clearances from all planned jurisdictions for our global Phase 2 study and are advancing start up activities.”
Eric Easom, Co-Founder, Chairman, President and CEO
“Beyond our clinical stage pipeline, the selection of AN2-504661 for HPP as our second development candidate this year, further demonstrates the productivity of our research organization and the potential of our boron chemistry platform to generate differentiated therapies across multiple disease areas.”
Eric Easom, Co-Founder, Chairman, President and CEO
AN2 Therapeutics Insider Joshua M. Eizen Sells $11.9K of Stock
Joshua M. Eizen sold 2,826 shares of AN2 Therapeutics, Inc. at $4.22 a share, worth $11.9K in total on Nov 5, 2026. Shares held after the trade: 207,546 (-1.3%).
- Value
- $11.9K
- Shares
- 2,826
- Price
- $4.22
- Holding change
- -1.3%
- Trade date
- Nov 5, 2026